BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Exclusion Criteria

• •Subjects who have been exposed to BOL-303259-X within 3 months prior to Visit 1 (Screening).
• •Subjects with a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the results of the study.
• •Subjects with an irregular daily sleep schedule.
• •Subjects who are unable to wear sleep monitoring device for 7 days prior to laboratory study.
• •Subjects with an anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP.
• •Subjects for whom concomitant use of medications may interact with the safety or efficacy of a nitric oxide.
• •Subjects with known hypersensitivity or contraindications to latanoprost or any of the ingredients in the study drugs.
• •Subjects who are expected to require treatment with ocular or systemic corticosteroids.
• •Subjects who are in need of any other topical or systemic treatment of OAG or OHT.
• •Subjects who are unable to discontinue contact lens use during and for 24 hours before the laboratory study.
• •Subjects with a central corneal thickness greater than 600 μm in either eye.
• •Subjects with any condition that prevents reliable applanationtonometry in either eye.
• •Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.
• •Subjects with previous or active corneal disease.
• •Subjects with a history of severe dry eye.
• •Subjects with active optic disc hemorrhage.
• •Subjects with a history of central/branch retinal vein or artery occlusion.
• •Subjects with a history of macular edema.
• •Subjects with very narrow angles and subjects with angle closure, congenital, and secondary glaucoma, and subjects with history of angle closure in either eye.
• •Subjects with a diagnosis of a clinically significant or progressive retinal disease in either eye.
• •Subjects with any intraocular infection or inflammation within 3 months prior to Visit 1 (Screening).
• •Subjects with a history of ocular laser surgery within the 3 months prior to Visit 1 (Screening).
• •Subjects with a history of incisional ocular surgery or severe trauma within 3 months prior to Visit 1 (Screening).